Zahra Sahaf
About Zahra Sahaf
Zahra Sahaf is a Senior Research Associate in Cell Engineering at Notch Therapeutics in Toronto, Canada, with a strong background in molecular biology and biotechnology. She has over seven years of experience in medical laboratory settings and has contributed to significant research projects in gene editing and T-cell differentiation.
Work at Notch Therapeutics
Zahra Sahaf serves as a Senior Research Associate in Cell Engineering at Notch Therapeutics, a position she has held since 2021. In this role, she focuses on advancing research in cell engineering, contributing her expertise in molecular biology and related fields. Her work involves collaboration with cross-functional teams to enhance research outcomes and drive continuous improvement within the organization.
Education and Expertise
Zahra Sahaf holds a Master's degree in Biotechnology from McGill University - Macdonald Campus, which she completed between 2016 and 2017. She also earned a Bachelor's degree in Microbiology from Islamic Azad University from 1999 to 2003. Her educational background supports her diverse skill set, which includes molecular biology, biochemistry, microbiology, proteomics, and cell biology.
Background
Prior to her current role, Zahra Sahaf accumulated extensive experience in medical laboratory settings, totaling seven years. She worked in various departments, including hematology, microbiology, serology, immunology, and biochemistry. Her previous positions include roles at Pishtaz Teb as an ELISA Specialist and Quality Control Analyst, as well as research roles at McGill University and Université de Montréal.
Achievements
Zahra Sahaf has been involved in significant research projects, including the MAD7-based gene editing platform for induced pluripotent stem cell (iPSC) engineering. She contributed to research on DLL4 and VCAM for T-cell differentiation and participated in the presentation at the Keystone conference on Emerging Cellular Therapies in January 2023. Additionally, she attended the Society for Immunotherapy of Cancer (SITC) 2023 conference, furthering her engagement in the field.